{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:19:40Z","timestamp":1792783180697,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Heart and Stroke Foundation of Canada (CA) - Alberta","id":[{"id":"https:\/\/ror.org\/00qbpyp73","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs Program","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00415-020-10335-2","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T13:03:05Z","timestamp":1609678985000},"page":"1837-1846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Early apixaban therapy after ischemic stroke in patients with atrial fibrillation"],"prefix":"10.1007","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-6920","authenticated-orcid":false,"given":"Anas","family":"Alrohimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Jickling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashfaq","family":"Shuaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibi","family":"Thirunavukkarasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken S.","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"issue":"5","key":"10335_CR1","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1161\/01.STR.14.5.688","volume":"14","author":"RG Hart","year":"1983","unstructured":"Hart RG, Coull BM, Hart D (1983) Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. Stroke 14(5):688\u2013693","journal-title":"Stroke"},{"key":"10335_CR2","first-page":"CD000024","volume":"3","author":"PA Sandercock","year":"2015","unstructured":"Sandercock PA, Counsell C, Kane EJ (2015) Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 3:CD000024","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10335_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1161\/01.STR.0000254600.92975.1f","volume":"38","author":"M Paciaroni","year":"2007","unstructured":"Paciaroni M, Agnelli G, Micheli S, Caso V (2007) Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 38(2):423\u2013430","journal-title":"Stroke"},{"issue":"6","key":"10335_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S1474-4422(13)70079-6","volume":"12","author":"WN Whiteley","year":"2013","unstructured":"Whiteley WN, Adams HP Jr, Bath PM, Berge E, Sandset PM, Dennis M et al (2013) Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurol 12(6):539\u2013545","journal-title":"Lancet Neurol"},{"issue":"4","key":"10335_CR5","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/1747493017743062","volume":"13","author":"T Wein","year":"2018","unstructured":"Wein T, Lindsay MP, Cote R, Foley N, Berlingieri J, Bhogal S et al (2018) Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. Int J Stroke 13(4):420\u2013443","journal-title":"Int J Stroke"},{"issue":"3","key":"10335_CR6","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","volume":"49","author":"WJ Powers","year":"2018","unstructured":"Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K et al (2018) 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 49(3):e46\u2013e110","journal-title":"Stroke"},{"issue":"11","key":"10335_CR7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981\u2013992","journal-title":"N Engl J Med"},{"key":"10335_CR8","unstructured":"Canada. PCUB-MS. Eliquis (Apixaban) Product Monograph. Date on initial approval 13 December 2011. Revised 07 October 2019. 4\/83"},{"issue":"27","key":"10335_CR9","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1093\/eurheartj\/eht134","volume":"34","author":"H Heidbuchel","year":"2013","unstructured":"Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J et al (2013) EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 34(27):2094\u20132106","journal-title":"Eur Heart J"},{"issue":"6","key":"10335_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/0895-6111(89)90285-1","volume":"13","author":"RA Robb","year":"1989","unstructured":"Robb RA, Hanson DP, Karwoski RA, Larson AG, Workman EL, Stacy MC (1989) Analyze: a comprehensive, operator-interactive software package for multidimensional medical image display and analysis. Comput Med Imaging Graph 13(6):433\u2013454","journal-title":"Comput Med Imaging Graph"},{"issue":"11","key":"10335_CR11","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1161\/01.STR.30.11.2280","volume":"30","author":"M Fiorelli","year":"1999","unstructured":"Fiorelli M, Bastianello S, von Kummer R, del Zoppo GJ, Larrue V, Lesaffre E et al (1999) Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 30(11):2280\u20132284","journal-title":"Stroke"},{"issue":"7","key":"10335_CR12","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1161\/01.STR.31.7.1770","volume":"31","author":"PM Bath","year":"2000","unstructured":"Bath PM, Iddenden R, Bath FJ (2000) Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials. Stroke 31(7):1770\u20131778","journal-title":"Stroke"},{"issue":"6","key":"10335_CR13","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.jvs.2009.09.044","volume":"50","author":"MS Conte","year":"2009","unstructured":"Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR, Moneta GL et al (2009) Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 50(6):1462-1473e.3","journal-title":"J Vasc Surg."},{"key":"10335_CR14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1136\/neurintsurg-2019-015535","volume":"12","author":"D Fiorella","year":"2020","unstructured":"Fiorella D, Gache L, Frame D, Arthur AS (2020) How safe and effective are flow diverters for the treatment of unruptured small\/medium intracranial aneurysms of the internal carotid artery? Meta-analysis for evidence-based performance goals. J Neurointerv Surg. 12:869\u2013873","journal-title":"J Neurointerv Surg."},{"issue":"3","key":"10335_CR15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.athoracsur.2006.06.037","volume":"82","author":"GL Grunkemeier","year":"2006","unstructured":"Grunkemeier GL, Jin R, Starr A (2006) Prosthetic heart valves: objective performance criteria versus randomized clinical trial. Ann Thorac Surg 82(3):776\u2013780","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"10335_CR16","doi-asserted-by":"publisher","first-page":"e31115","DOI":"10.1371\/journal.pone.0031115","volume":"7","author":"N Bansback","year":"2012","unstructured":"Bansback N, Tsuchiya A, Brazier J, Anis A (2012) Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS ONE 7(2):e31115","journal-title":"PLoS ONE"},{"issue":"10","key":"10335_CR17","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2017.2161","volume":"74","author":"KS Hong","year":"2017","unstructured":"Hong KS, Kwon SU, Lee SH, Lee JS, Kim YJ, Song TJ et al (2017) Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation-related mild ischemic stroke: a randomized clinical trial. JAMA Neurol 74(10):1206\u20131215","journal-title":"JAMA Neurol"},{"issue":"4","key":"10335_CR18","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1161\/STROKEAHA.119.027569","volume":"51","author":"KS Butcher","year":"2020","unstructured":"Butcher KS, Ng K, Sheridan P, Field TS, Coutts SB, Siddiqui M et al (2020) Dabigatran treatment of acute noncardioembolic ischemic stroke. Stroke 51(4):1190\u20131198","journal-title":"Stroke"},{"issue":"6","key":"10335_CR19","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/ijs.12452","volume":"10","author":"K Toyoda","year":"2015","unstructured":"Toyoda K, Arihiro S, Todo K, Yamagami H, Kimura K, Furui E et al (2015) Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study. Int J Stroke 10(6):836\u2013842","journal-title":"Int J Stroke"},{"issue":"12","key":"10335_CR20","doi-asserted-by":"publisher","first-page":"e007034","DOI":"10.1161\/JAHA.117.007034","volume":"6","author":"M Paciaroni","year":"2017","unstructured":"Paciaroni M, Agnelli G, Falocci N, Tsivgoulis G, Vadikolias K, Liantinioti C et al (2017) Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin-K oral anticoagulants (RAF-NOACs) study. J Am Heart Assoc 6(12):e007034","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"10335_CR21","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1212\/WNL.0000000000003283","volume":"87","author":"DJ Seiffge","year":"2016","unstructured":"Seiffge DJ, Traenka C, Polymeris A, Hert L, Peters N, Lyrer P et al (2016) Early start of DOAC after ischemic stroke: risk of intracranial hemorrhage and recurrent events. Neurology 87(18):1856\u20131862","journal-title":"Neurology"},{"key":"10335_CR22","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/jnnp-2018-318890","volume":"90","author":"D Wilson","year":"2018","unstructured":"Wilson D, Ambler G, Banerjee G, Shakeshaft C, Cohen H, Yousry TA et al (2018) Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study. J Neurol Neurosurg Psychiatry 90:320\u2013325","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10335_CR23","unstructured":"Paciaroni M. Agnelli G. Giustozzi M et al. (2020) Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. Eur Stroke J 1\u201310"},{"issue":"7","key":"10335_CR24","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1161\/STROKEAHA.116.013491","volume":"47","author":"LC Gioia","year":"2016","unstructured":"Gioia LC, Kate M, Sivakumar L, Hussain D, Kalashyan H, Buck B et al (2016) Early rivaroxaban use after cardioembolic stroke may not result in hemorrhagic transformation: a prospective magnetic resonance imaging study. Stroke 47(7):1917\u20131919","journal-title":"Stroke"},{"key":"10335_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/cjn.2020.84","volume":"47","author":"A Alrohimi","year":"2020","unstructured":"Alrohimi A, Ng K, Dowlatshahi D, Buck B, Stotts G, Thirunavukkarasu S et al (2020) Early dabigatran treatment after transient ischemic attack and minor ischemic stroke does not result in hemorrhagic transformation. Can J Neurol Sci. 47:1\u201322","journal-title":"Can J Neurol Sci."},{"key":"10335_CR26","doi-asserted-by":"publisher","first-page":"116582","DOI":"10.1016\/j.jns.2019.116582","volume":"409","author":"AI Al Bakr","year":"2020","unstructured":"Al Bakr AI, AlOmar RS, Nada MAF, Ishaque N, Aljaafari D, Hadhiah K et al (2020) Timing to start anticoagulants after acute ischemic stroke with non-valvular atrial fibrillation. J Neurol Sci 409:116582","journal-title":"J Neurol Sci"},{"issue":"3","key":"10335_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11239-016-1393-9","volume":"42","author":"M Cappellari","year":"2016","unstructured":"Cappellari M, Carletti M, Danese A, Bovi P (2016) Early introduction of direct oral anticoagulants in cardioembolic stroke patients with non-valvular atrial fibrillation. J Thromb Thrombolysis 42(3):393\u2013398","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"10335_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/1747493016632239","volume":"11","author":"S Arihiro","year":"2016","unstructured":"Arihiro S, Todo K, Koga M, Furui E, Kinoshita N, Kimura K et al (2016) Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: the SAMURAI-nonvalvular atrial fibrillation (NVAF) study. Int J Stroke 11(5):565\u2013574","journal-title":"Int J Stroke"},{"key":"10335_CR29","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1161\/STROKEAHA.120.028867","volume":"51","author":"S Yaghi","year":"2020","unstructured":"Yaghi S, Mistry E, Liberman AL, Giles J, Asad SD, Liu A et al (2020) Anticoagulation type and early recurrence in cardioembolic stroke: the IAC study. Stroke 51:2724\u20132732","journal-title":"Stroke"},{"issue":"8","key":"10335_CR30","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1161\/STROKEAHA.115.008891","volume":"46","author":"M Paciaroni","year":"2015","unstructured":"Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S et al (2015) Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. Stroke 46(8):2175\u20132182","journal-title":"Stroke"},{"issue":"12","key":"10335_CR31","first-page":"860","volume":"38","author":"HC Diener","year":"2017","unstructured":"Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J et al (2017) Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 38(12):860\u2013868","journal-title":"Eur Heart J"},{"issue":"1","key":"10335_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1161\/STROKEAHA.109.563767","volume":"41","author":"K Butcher","year":"2010","unstructured":"Butcher K, Christensen S, Parsons M, De Silva DA, Ebinger M, Levi C et al (2010) Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation. Stroke 41(1):72\u201377","journal-title":"Stroke"},{"key":"10335_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1474-4422(18)30356-9","volume":"18","author":"DJ Seiffge","year":"2018","unstructured":"Seiffge DJ, Werring DJ, Paciaroni M, Dawson J, Warach S, Milling TJ et al (2018) Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol 18:117\u2013126","journal-title":"Lancet Neurol"},{"issue":"1","key":"10335_CR34","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s13063-017-2313-9","volume":"18","author":"S Asberg","year":"2017","unstructured":"Asberg S, Hijazi Z, Norrving B, Terent A, Ohagen P, Oldgren J (2017) Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial. Trials 18(1):581","journal-title":"Trials"},{"key":"10335_CR35","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3389\/fneur.2019.00975","volume":"10","author":"DZ Rose","year":"2019","unstructured":"Rose DZ, Meriwether JN, Fradley MG, Renati S, Martin RC, Kasprowicz T et al (2019) Protocol for AREST: apixaban for early prevention of recurrent embolic stroke and hemorrhagic transformation\u2014a randomized controlled trial of early anticoagulation after acute ischemic stroke in atrial fibrillation. Front Neurol 10:975","journal-title":"Front Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10335-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-10335-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10335-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T01:41:52Z","timestamp":1619314912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-10335-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10335"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10335-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"23 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KB reports grants and personal fees from Boehringer Ingleheim, grants and personal fees from BMS-Pfizer Alliance, grants and personal fees from Bayer, grants and personal fees from Servier Canada, outside the submitted work. AA, BB, GJ, AS, and ST have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The research protocol was approved by our local Human Research Ethics Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all subjects before the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Dr. Butcher was the Principal Investigator, responsible for protocol design, funding, and overall conduct of the study, as well as manuscript preparation. Dr. Alrohimi led patient recruitment, performed all image and statistical analyses and wrote the initial draft of the manuscript. Brian Buck, Glen Jickling, Ashfaq Shuaib, and Sibi Thirunavukkarasu recruited patients and made critical revisions of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of authorship"}}]}}